<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016859</url>
  </required_header>
  <id_info>
    <org_study_id>IPF-2013-Rambam</org_study_id>
    <nct_id>NCT02016859</nct_id>
  </id_info>
  <brief_title>Observational Prospective Study of the Predicted Value of Immature Thrombocytes Counts in Three Different Groups of Critically Ill Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Yishai Ofran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Helsinki Commitee-Rambam Medical Center</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immature Platelet Fraction (IPF) is a new value in CBC blood tests Recent Studies showed
      that this value may be another prognostic factor in critically ill patients such as those
      admitted to ICU, or those with neutropenic Fever.

      The purpose of the study is to check if the IPF may be used as a prognostic Factor in these
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we have 3 groups of patients

        -  Patients admitted to ICU

        -  Patients admitted with neutropenic fever

        -  Patients admitted with hip fractures it is a prospective study, not interventional,
           we'll take blood samples of these patients including CBC count eith IPF and other
           inflammation markers such as CRP and we'll compare CRP to IPF in addition to clinical
           follow-up of the patient till discharge.

      At the end of this study we'll compare the efficacy of IPF as a prognostic Factor in these
      patients
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Time to recovery from sepsis or time to death</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the primary outcome is the result of the patient's admission on which data analysis will be based</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predicting value of IPF for prognosis</measure>
    <time_frame>baeline 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>after the analysis of the data we'll may ba able to assess the predicting value of the IPF in predicting severity of infection and prediciting prognosis of infection in the three groups described</description>
  </secondary_outcome>
  <other_outcome>
    <measure>clinical use of IPF as a prognostic factor</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>this outcome is not uet based we need much more studies in order to be able to use IPF in daily clinical work</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Critically Ill Patients</condition>
  <condition>Neutropenic Fever Patients</condition>
  <condition>Patients With Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Critically ill patients admitted to ICU</arm_group_label>
    <description>those patients who are admitted to ICU with multiorgan failure/injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neutropinc Fever patients</arm_group_label>
    <description>admitted to ER, haemato-oncology or oncology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients of Hip's  Fracture</arm_group_label>
    <description>admitted to orthopedic departement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immature Platelet Fraction</intervention_name>
    <arm_group_label>Critically ill patients admitted to ICU</arm_group_label>
    <arm_group_label>Neutropinc Fever patients</arm_group_label>
    <arm_group_label>Patients of Hip's  Fracture</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        admmitted patients to multiple departements
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Admission to hospital blood sample is taken between 24:00 pm till 15:00 pm

        Exclusion Criteria:

          -  blood sample is taken after 15:00 pm in the first day of admission during the week

          -  blood sample is taken on weekend: thursday 15:00 pm till saturday 24:00 pm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yishai Ofran, Doctor</last_name>
    <phone>009720502061524</phone>
    <email>Y_ofran@ramabm.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doaa Okasha, doctor</last_name>
    <phone>009720502062701</phone>
    <email>d_okasha@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 15, 2013</lastchanged_date>
  <firstreceived_date>November 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Dr. Yishai Ofran</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>IPF Immature platelet fraction</keyword>
  <keyword>ICU neutropenic fever</keyword>
  <keyword>hip fracture</keyword>
  <keyword>critically ill</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
